Abstract: An apparatus, method, and device for encapsulating heterogeneous functional equivalents are disclosed. The apparatus includes a redundancy controller, an input proxy, and an output proxy. In this application, a plurality of heterogeneous functional equivalents are encapsulated by an input proxy and an output proxy, so that the apparatus can support adaptation, normalization and dis-cooperation to cut a communication link employed by an attacker, such that it is difficult for the attacker to sniff and exploit unknown defects or backdoors, and a success rate of the attacker attacking an information system is reduced.

Abstract: The invention provides compounds of formula (I): or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases and release an active metabolite in vivo. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat inflammatory skin diseases and other diseases.

Abstract: The invention relates to an assembly comprising a crankpin which includes a ball joint, and a connecting rod which carries a ball joint housing, wherein the ball joint housing and the connecting rod are assembled by a bayonet mounting, and wherein the connecting rod comprises a locking hole through which an axial section of the ball joint housing passes, the connecting rod comprises at least one locking lug, the ball joint housing comprises a locking notch which is defined by two opposing radial faces, characterized in that one of the two opposing radial faces of the locking notch and one facing face of the locking lug each have a complementary inclined profile in order, during the rotation, to cause an axial clamping of the locking lug in-side the locking notch.

Abstract: The invention relates to a wipe suitable for application to a hard surface comprising from 0.0001 to 5 wt. % of a lactam; to the use of said wipe on a surface to reduce microorganism buildup on said surface; and, to the use of a lactam in a wipe product to enhance preservation of said wipe product.

Abstract: The present invention provides a crystal of the compound represented by formula (I) having applicability as a drug substance of pharmaceuticals.

Abstract: A tri-directional bracket, system, and method is for displaying information is disclosed. The bracket includes a set of sides connected to each other defining a generally triangular prism, a first end cap connected to the set of sides at a first end, a second end cap, connected to the set of sides at a second end, a stop cap connected to the set of sides, positioned between the first end and the second end, and a guide connected to the set of sides, positioned between the stop cap and the second end cap. A handle is connected to the first end cap. A 360-degree viewing angle defined by the set of sides. A set of displays is connected to the tri-directional bracket and a computing device is connected to the set of displays to display information. The bracket is then connected to a mounting structure, such as a tripod.

Abstract: Compositions of proteoglycans and core proteins thereof and related methods of treating subjects, e.g., patients, are described. The method may include applying a composition to an eye of a subject before, during, and/or after an intraocular medical procedure. The composition may comprise a proteoglycan or core protein thereof, such as decorin proteoglycan or decorin core protein, and a pharmaceutically-acceptable salt. The composition may be in the form of an aqueous solution, viscoelastic gel, or viscoelastic film, for example. Further methods are described that include treating donor corneal tissue with a composition comprising a proteoglycan or core protein thereof. The treated donor corneal tissue may be used as or in a corneal graft, such as during endothelial keratoplasty.

Abstract: A laundry serum composition comprising: 0.5 to 15 w.t. % non-ionic surfactant; 0.5 to 40 w.t. % benefit agents; and water.

Abstract: Compositions of proteoglycans and core proteins thereof and related methods of treating subjects, e.g., patients, are described. The method may include applying a composition to an eye of a subject before, during, and/or after an intraocular medical procedure. The composition may comprise a proteoglycan or core protein thereof, such as decorin proteoglycan or decorin core protein, and a pharmaceutically-acceptable salt. The composition may be in the form of an aqueous solution, viscoelastic gel, or viscoelastic film, for example. Further methods are described that include treating donor corneal tissue with a composition comprising a proteoglycan or core protein thereof. The treated donor corneal tissue may be used as or in a corneal graft, such as during endothelial keratoplasty.

Abstract: Systems and methods are disclosed for making three-dimensional models of the inside of an ear canal using a projected pattern. A system comprises a probe adapted to be inserted into the ear canal. The probe comprises a narrow portion adapted to fit inside the ear canal and a wide portion adapted to be wider than the ear canal, which may be formed by a tapered stop. An illumination subsystem projects a pattern of light from the distal end of the probe onto a surface of the ear canal, the pattern being modulated by the three-dimensional surface of the ear canal. An imaging subsystem captures a series of individual images of the pattern of light projected onto the surface of the ear canal. A computer subsystem calculates digital three-dimensional representations from the individual images and stitches them together to generate a digital three-dimensional model of the ear canal.

Abstract: The disclosed apparatus, systems and methods relate a failover and internet connection monitoring system featuring a cloud server running an API, a probe, a firewall and a policy routing system. The failover connection monitoring system is capable of gathering and analyzing performance data and controlling the flow of packets to and from the internet over one or more connections to optimize performance of the network.

Abstract: The present invention discloses a structure monitoring system comprising a plurality of marking units disposed on a structural object, a monitoring device monitoring the plurality of marking units remotely, and a data processing device connected to the monitoring device. The aforementioned data processing device further comprises a data receiving module and a data processing module. The data receiving module receives a data detected by the monitoring device, and the data processing module calculates and analyzes the information. In addition, a structural monitoring method has also been provided.

Abstract: There is provided a therapeutic agent for Alzheimer's disease for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (I): or a pharmaceutically acceptable salt thereof, and memantine represented by formula (II): or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to solid state forms of 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione hydrochloride compound of formula-1a and their processes for the preparation thereof and an improved process for the preparation of 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione hydrochloride. The present inventors also provides an amorphous polymorph of the combination drug consisting of 2?-deoxy-5-(trifluoromethyl) uridine and 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione monohydrochloride and its process for the preparation.

Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Abstract: A transmission testing device that can highly accurately reproduce behavior of an actual engine includes a drive dynamometer DM1 connected to an input shaft of a transmission, absorption dynamometers DM2 and DM3 that are connected to output shafts of the transmission, a shaft torque detection unit that detects a shaft torque value generated at the input shaft of the transmission, and a control unit that controls the drive dynamometer DM1. The control unit uses the shaft torque value detected by the shaft torque detection unit to generate a shaft torque correction value for the drive dynamometer DM1, receives an engine torque input value and uses the received engine torque input value to generate an engine torque correction value for the drive dynamometer DM1, and controls the drive dynamometer DM1 on the basis of a torque command value generated from the shaft torque correction value and the engine torque correction value.

Abstract: A method for enabling hybrid beamforming in a communication system including a transmitter being able to serve a plurality of receivers, wherein a frequency band comprises at least one subcarrier, wherein each receiver is associated to a set Cprec,k of analog precoding codewords, said method comprising: —for each receiver, computing (202) an analog precoding matrix FRF k associated to said receiver; said computation (202) comprising: /a/ for each subcarrier, performing (202a) a Singular Value Decomposition, SVD, on a channel matrix associated to said receiver and to said each subcarrier; /b/ for each subcarrier, determining a first decomposition matrix Vk(1) based on the relative SVD; /c/ determining (303) an analog precoding codeword which optimizes a first function g1(Vk(1), . . . , Vk(L), F) of Vk(1), . . . , Vk(L) and F, for a plurality of F E Cprec,k, wherein L denotes a number of subcarriers.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.